FDA Approves Afamitresgene Autoleucel for Patients With Unresectable or Metastatic Synovial Sarcoma

Clinical Summary: 

• Based on results from the SPEARHEAD-1 trial the FDA has approved afamitresgene autoleucel for patients with unresectable or metastatic synovial sarcoma who received prior chemotherapy and had MAGE-A4–positive tumors.
• Afamitresgene autoleucel achieved an overall response rate of 43.8%, including complete responses, with nearly one-third of responders maintaining responses for at least 24 months.
• The approval converts the prior accelerated approval to full approval and expands eligibility to include pediatric patients aged 12 years and older with biomarker-eligible synovial sarcoma.

On June 22, 2026, the US Food and Drug Administration (FDA) granted full approval to afamitresgene autoleucel (Tecelra, US WorldMeds) for adult and pediatric patients aged 12 years and older with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A02:01P, -A02:02P, -A02:03P, or -A02:06P positive, and whose tumors express the MAGE-A4 antigen, as determined by an FDA-approved or cleared companion diagnostic test. This approval was based on results from the SPEARHEAD-1 study.

In this open-label, single-arm study, 137 patients with advanced synovial sarcoma received afamitresgene autoleucel, an autologous engineered T-cell therapy manufactured from a patient's own white blood cells and genetically modified to recognize and target MAGE-A4–expressing tumor cells. The primary efficacy end point was overall response rate (ORR) as assessed by independent review and supported by duration of response.

At analysis, ORR was 43.8%, with a complete response rate of 3.6%. Median duration of response was 5.3 months. Among patients who responded to treatment, 31.9% maintained a response for at least 24 months. 

The most common adverse reactions included nausea, fatigue, infection, pyrexia, constipation, vomiting, headache, diarrhea, tachycardia, cough, elevated aspartate aminotransferase, elevated alanine aminotransferase, lymphopenia, leukopenia, neutropenia, anemia, and thrombocytopenia. Patients receiving afamitresgene autoleucel require close monitoring following infusion because severe or life-threatening adverse reactions may occur.

Afamitresgene autoleucel initially received accelerated approval in August 2024 and became the first engineered T-cell therapy approved for a solid tumor in the United States. The expanded indication now includes eligible pediatric patients aged 12 years and older, broadening access to this personalized cellular therapy for patients with biomarker-defined advanced synovial sarcoma.

“The availability of an engineered cell therapy for adolescents introduces an important new option for patients who are biomarker-eligible, allowing us to incorporate this approach into treatment planning based on the same evidence that has guided adult care,” said Amy Armstrong, MD, Washington University School of Medicine, St. Louis, Missouri.

Source:

PR Newswire. US WorldMeds® receives full U.S. FDA approval of TECELRA® (afamitresgene autoleucel) with an expanded Indication, extending the first approved engineered T-cell therapy for a solid tumor to children as young as 12. Accessed on June 23, 2026. https://www.prnewswire.com/news-releases/us-worldmeds-receives-full-us-fda-approval-of-tecelra-afamitresgene-autoleucel-with-an-expanded-indication-extending-the-first-approved-engineered-t-cell-therapy-for-a-solid-tumor-to-children-as-young-as-12-302806599.html